The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.
 
Michael Ong
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Novartis / AAA; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer/EMD Serono; Sanofi
Research Funding - AstraZeneca (Inst); BMS (Inst)
Travel, Accommodations, Expenses - Janssen
 
Hiroyoshi Suzuki
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Janssen Oncology; Janssen Research & Development; Lilly; MSD K.K; Nihon Medi-Physics; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Daiichi-Sankyo; Janssen; Kissei Pharmaceutical; Nippon Shinyaku; Novartis; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); Nihonkayaku (Inst)
 
Matthew Smith
Consulting or Advisory Role - Ambrx; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Oncternal Therapeutics; Pfizer
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst)
 
Bertrand Tombal
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen
Research Funding - Ferring (Inst)
Expert Testimony - Steba Biotech
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Maha Hussain
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Novartis; Pfizer; Tango Therapeutics; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Bayer
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Tolmar
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Pfizer
 
Frank Verholen
Employment - Bayer
Travel, Accommodations, Expenses - Bayer
 
Ha Pham
Consulting or Advisory Role - Bayer
Research Funding - Bayer (Inst)
 
Shankar Srinivasan
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Patents, Royalties, Other Intellectual Property - Inventor on BMS Patent
 
Aly-Khan Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)